Navigation Links
Kendle Executive Dennis Hurley, DrSc to Present Keynote Address at DIA Latin American Congress 2007
Date:9/27/2007

Presentation to Encourage Careers in Clinical Development, Highlight Professional Development Opportunities Throughout Latin American Region

CINCINNATI, Sept. 27 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced that Vice President, Global Clinical Development - Latin America, Dennis Hurley, DrSc will give the keynote address at the DIA 4th Latin American Congress of Clinical Research on Friday, Sept. 28 at 9 a.m. The presentation, titled "Professional Development and Latin America Development," will encourage young professionals and students to pursue careers in the expanding field of clinical research. Additional Kendle participants in the presentation include Alcione Braga, RPh, Director, Global Clinical Development -- Latin America, Brazil; Maria Hurley, MBA, HR Manager, Latin America; and Daniel Mazzolenis, MD, MBA, Project Leader, Argentina.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )

"Careers in clinical research are incredibly fulfilling," says Dr. Hurley. "Beyond the financial benefits, professionals in our industry are quite passionate and take great pride in conducting research to develop life-saving and enhancing drugs that relieve human suffering. Anyone considering a career in this rewarding and rapidly growing field can be assured that there is high demand for skilled professionals, and that there is an abundance of opportunities to develop the skills needed to succeed."

Dr. Hurley's presentation will demonstrate how the clinical development field meets three key criteria for a rewarding career and also will highlight the many programs available throughout Latin America where students and professionals alike can acquire the marketable skills needed to advance in the industry.

The presentation will be available on http://www.kendle.com in the "Industry Events" section following the completion of the program.

Kendle in Latin America

Kendle provides full-service drug development programs for clinical trials in Latin America, With a base of operations in Mexico and offices in Argentina, Brazil, Chile, Colombia and Peru, six countries representing more than 80 percent of the region's population, Kendle offers an industry-leading footprint in Latin America.

In addition to ensuring the orderly, GCP-compliant conduct of clinical trials activities in this region of the world, Kendle's Latin America staff posses the in-depth experience required to conduct local clinical trial materials management and distribution as well as provide regulatory and safety services in-house. Having these services in house ensures greater control and accuracy throughout the process.

The advantages of conducting clinical trials in Latin America include:

- Solid regulatory framework with predictable timelines and reliable

processes in line with international GCP guidelines

- Access to nearly 200 million pediatric patients

- High quality data as confirmed by FDA and sponsor audits

- Hispanic and African descent populations, which are often

under-represented in clinical studies

- Expedited enrollment, with average enrollment of three to five times

faster than in traditional regions

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is among the world's leading global clinical research organizations and is the fourth-largest provider of Phase II-IV clinical development services worldwide. We deliver innovative and robust clinical development solutions -- from first-in-human studies through market launch and surveillance -- to help the world's biopharmaceutical companies maximize product life cycles and grow market share.

Our global clinical development business is focused on five regions -- North America, Europe, Asia/Pacific, Latin America and Africa -- to meet customer needs. With the expertise of our more than 3,000 associates worldwide, Kendle has conducted clinical trials and provided regulatory and pharmacovigilance services in more than 80 countries. The company was named the "Top CRO to Work With" in the Thomson CenterWatch 2007 Survey of U.S. Investigative Sites.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company's Web site at http://www.kendle.com.

Forward-Looking Statements

This release contains information about management's view of Kendle's future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, those set forth in the "Risk Factors" section of the Company's latest Form 10-K and other filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point, the Company specifically disclaims any obligation to do so other than as required by federal securities laws. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.


'/>"/>
SOURCE Kendle
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Where Burnt Out Executives De-stress in Natures Lap
2. Asian Business Executives Urged to Be Eco-friendly
3. BMA Welcomes Scottish Executives Move to Raise the Purchase Age of Cigarettes
4. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
5. Researchers Present Ways To Reduce The Risk Of Dementia
6. Researchers Present Data Regarding The Efficiency Of Herbs
7. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
8. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
9. Drug Reactions First Present Themselves In The Mouth
10. Reminiscing Into The Past Makes You Dissatisfied With The Present
11. Living In The Past Indicates Dissatisfaction With Present
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: